[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperopia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperopia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,77,101,127,145,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641841","corneal-epithelial-thickness-mapping-by-anterior-segment-optical-coherence-tomography-in-patients-with-refractive-errors-100641841",false,"NCT07647146","Corneal Epithelial Thickness Mapping by Anterior Segment Optical Coherence Tomography in Patients With Refractive Errors","Inclusion Criteria:\n\n* Age ≥ 18 years-\n* Patients diagnosed with myopia or hyperopia by refraction\n* Clear cornea with no evidence of corneal pathology\n* Ability to undergo reliable anterior segment imaging\n\nExclusion Criteria:\n\n* Inability to fixate or follow instructions\n* Family history of keratoconus\n* Glaucoma,Cataract\n* Previous ocular surgery including refractive surgery\n* Keratoconus or suspected corneal ectasia\n* Corneal opacities or scars\n* Contact lens wear within the last two weeks\n* Ocular trauma\n* systemic disease affecting the cornea ( Such as diabetes)",true,"ALL","18 Years","99 Years",{"count":20,"type":21},360,"ESTIMATED","OBSERVATIONAL","This study evaluates corneal epithelial thickness using anterior segment optical coherence tomography (AS-OCT) in patients with refractive errors. It aims to assess the relationship between epithelial thickness patterns and different types of refractive errors.",[25,26,27,28],"Myopia","Hyperopia","Astigmatism","Emmetropia",[30],"Corneal epithelial thickness, AS-OCT, anterior segment optical coherence tomography, refractive errors, myopia, hyperopia, astigmatism, cornea","NOT_YET_RECRUITING","2026-06-09",{"date":34,"type":35},"2026-06-15","ACTUAL",{"date":37,"type":21},"2026-07-01",{"date":39,"type":21},"2027-05-01",{"name":41,"class":42},"Sohag University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":15,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100623813","efficacy-of-stopkit-in-retarding-axial-length-growth-in-children-with-low-hyperopia-100623813","NCT07401511","Efficacy of S.T.O.P®KIT in Retarding Axial Length Growth in Children With Low Hyperopia","A Multicenter, Randomized Controlled Clinical Study Evaluating the Efficacy of Dynamic Spatiotemporal Optical Film (S.T.O.P®KIT) in Retarding Axial Length Growth in Children With Low Hyperopia","Inclusion Criteria:\n\n* Eligible study participants must meet all the following criteria: 1. Age: 6-10 years old;\n* +0.75D ≤ Spherical equivalent power ≤ +3.00D;\n* Anisometropia ≤ 1.50D;\n* Astigmatism ≤ 1.50D;\n* No participation in other myopia prevention and control studies or use of other myopia prevention and control methods (including low-concentration atropine eye drops, defocus eyeglasses, orthokeratology lenses, multifocal soft contact lenses, etc.) within 3 months;\n* Best-corrected visual acuity (BCVA) in both eyes ≥ 0.8 using a standard logarithmic visual acuity chart;\n* Ability to wear frame glasses during near work for at least 6 hours per day;\n* Study participants or their legal representatives sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with strabismus;\n* Patients with abnormal stereopsis;\n* Comorbidity with other ophthalmic diseases, including developmental abnormalities affecting visual function and refractive status;\n* Previous ocular surgery history;\n* Previous receipt of other myopia control treatments (including orthokeratology lenses, multifocal design soft contact lenses or frame glasses, drug therapy \\[atropine\\], visual training, etc.);\n* Current use of medications that may affect pupil size and ocular surface function;\n* Comorbidity with other systemic diseases that may affect visual function or refractive status;\n* Family history of hereditary ophthalmic diseases;\n* Other conditions deemed unsuitable for participation by investigators.","6 Years","10 Years",{"count":54,"type":21},180,"INTERVENTIONAL",[57],"NA","This is a multicenter, parallel-group, open-label, randomized controlled, superiority interventional clinical study initiated by investigators from Shanghai General Hospital (Study Protocol No.: IT-CRU-FAMB-001, Version V1.1, dated December 29, 2025), with Wang Xiaojuan as the principal investigator and the Department of Ophthalmology as the responsible department, collaborating with The First Affiliated Hospital of Zhengzhou University and Yantai Yuhuangding Hospital as participating centers. Launched on October 1, 2025, and scheduled to complete on April 1, 2027, the study aims to evaluate the efficacy of the Dynamic Spatiotemporal Optical Film (S.T.O.P®KIT) in retarding axial length growth in children with low hyperopia (primary endpoint) and compare the change in spherical equivalent power measured by autorefractometer under cycloplegia between the experimental and control groups (secondary endpoint). A total of 180 eligible children aged 6-10 years with low hyperopia will be randomly divided into the experimental group (90 cases) and the control group (90 cases) at a 1:1 ratio using simple randomization. The experimental group will receive two pairs of customized plano-spherical and plano-cylindrical glasses with S.T.O.P optical films of different phases (replaced at 6 months) and undergo follow-up every 3 months for 12 months, while the control group will only receive regular ophthalmic re-examinations without active intervention (with free dynamic optical films and customized glasses provided upon completion of all follow-ups). The study will adopt Analysis of Covariance (ANCOVA) for statistical analysis, with strict data management and quality control measures in place to ensure data authenticity and reliability, and will comply with the Declaration of Helsinki, Chinese GCP, and relevant ethical requirements to protect the safety, rights, and interests of study participants.",[60,26],"Children",[62,63,64,65,66],"children","axial length","low hyperopia","spherical equivalent","Dynamic Spatiotemporal Optical Film","2026-02-06",{"date":69,"type":35},"2026-02-10",{"date":71,"type":21},"2026-02-01",{"date":73,"type":21},"2027-08-01",{"name":75,"class":42},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",3,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":22,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100611430","assessing-the-turkish-ddivat-for-visual-acuity-measurement-100611430","NCT07240480","Assessing the Turkish DDIVAT for Visual Acuity Measurement","Validation of the Turkish Version of the DDIVAT Visual Acuity Measuring Device in a Turkish-speaking Population","Inclusion Criteria:\n\n* Adults aged 18 years or older\n\nTurkish-speaking individuals able to understand the study purpose\n\nWillingness to participate and provide written informed consent\n\nParticipants with or without refractive errors (e.g., myopia, hyperopia, astigmatism)\n\nExclusion Criteria:\n\n* Age below 18 years\n\nIndividuals unable to complete visual acuity testing\n\nPresence of severe ocular pathology (e.g., corneal opacity, retinal detachment) that prevents accurate measurement\n\nCognitive or communication difficulties preventing informed consent",{"count":85,"type":21},200,"1 Day","The goal of this observational methodological study is to validate the Turkish version of the DDIVAT visual acuity measuring device in a Turkish-speaking adult population.\n\nThe main questions it aims to answer are:\n\nDoes the Turkish version of the DDIVAT provide reliable and valid visual acuity measurements in Turkish speakers?\n\nAre the results of the DDIVAT comparable to those obtained with the standard Snellen chart used in clinical practice?\n\nResearchers will compare DDIVAT visual acuity test results with Snellen chart results to see if both methods produce consistent measurements.\n\nParticipants will:\n\nBe adults aged 18 years or older, including both patients and healthy volunteers.\n\nUndergo visual acuity testing using the DDIVAT system displayed on a smart TV connected to the university server.\n\nHave their visual acuity re-measured using the standard Snellen optotype under the same conditions.\n\nNo medication or invasive procedure will be used. The study carries no risk to participants.",[89,90,25,26,27],"Visual Acuity","Refractive Errors",[89,90],"2025-11-26",{"date":94,"type":35},"2025-12-04",{"date":96,"type":21},"2025-12-01",{"date":98,"type":21},"2026-05-31",{"name":100,"class":42},"Trakya University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":55,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":125,"locationsCount":43},"100603930","effect-of-light-blocking-lenses-on-pediatric-hyperopia-100603930","NCT07142915","Effect of Light-Blocking Lenses on Pediatric Hyperopia","A Prospective Randomized Controlled Trial on the Effect of Light-Blocking Lenses on Emmetropization in Hyperopic Children","Inclusion Criteria:\n\n* Aged 6 years or older and 12 years or younger;\n* Spherical refractive error in both eyes between +3.0 D and +7.5 D, cylindrical refractive error between -2.0 D and 0 D; interocular difference in spherical power less than 1.5 D and in cylindrical power no greater than 1.0 D;\n* Best-corrected visual acuity of 0.0 logMAR or better in both eyes;\n* Ocular deviation with spectacles less than 10 prism diopters;\n* Has been wearing standard single-vision spectacles regularly for more than six months;\n* In good general health, capable of receiving the study intervention, and willing to comply with the study protocol;\n* Written informed consent obtained from both the parent\u002Fguardian and the child, with agreement to comply with all study procedures and maintain follow-up availability throughout the study period;\n\nExclusion Criteria:\n\n* History of ocular trauma or eye surgery;\n* Presence of pathological abnormalities on anterior or posterior segment examination, or a history of organic ocular diseases such as cataract, glaucoma, corneal disease, or fundus disorders;\n* Intraocular pressure greater than 21 mmHg;\n* Presence of systemic diseases or other conditions deemed unsuitable for study participation;\n* Any other condition deemed inappropriate for participation in the clinical trial by the investigator;","12 Years",{"count":110,"type":21},156,[57],"This study aims to assess the efficacy of light-blocking lenses in facilitating emmetropization in children with hyperopia and to explore their influence on various aspects of visual function.",[26],[115,116,117,118],"hyperopia","light-blocking lenses","emmetropization","visual function","2025-08-25",{"date":121,"type":35},"2025-08-27",{"date":119,"type":21},{"date":124,"type":21},"2027-06-30",{"name":126,"class":42},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":108,"enrollmentInfo":134,"targetDuration":4,"studyType":55,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":144,"locationsCount":43},"100603931","effect-of-light-blocking-lenses-on-hyperopic-anisometropic-children-100603931","NCT07142928","Effect of Light-Blocking Lenses on Hyperopic Anisometropic Children","A Prospective Randomized Controlled Trial on the Effect of Light-Blocking Lenses on Emmetropization in Hyperopic Anisometropic Children","Inclusion Criteria:\n\n* Aged 6 years or older and 12 years or younger;\n* The more hyperopic eye has a spherical refractive error between +3.0 D and +7.5 D; the less hyperopic eye has a spherical refractive error of at least +2.0 D; cylindrical refractive error between -2.0 D and 0 D; interocular difference in spherical power \\>=1.5 D and in cylindrical power \\\u003C=1.0 D;\n* Best-corrected visual acuity of 0.0 logMAR or better in both eyes;\n* Ocular deviation with spectacles less than 10 prism diopters;\n* Has been wearing standard single-vision spectacles regularly for more than six months;\n* In good general health, capable of receiving the study intervention, and willing to comply with the study protocol;\n* Written informed consent obtained from both the parent\u002Fguardian and the child, with agreement to comply with all study procedures and maintain follow-up availability throughout the study period;\n\nExclusion Criteria:\n\n* History of ocular trauma or eye surgery;\n* Presence of pathological abnormalities on anterior or posterior segment examination, or a history of organic ocular diseases such as cataract, glaucoma, corneal disease, or fundus disorders;\n* Intraocular pressure greater than 21 mmHg;\n* Presence of systemic diseases or other conditions deemed unsuitable for study participation;\n* Any other condition deemed inappropriate for participation in the clinical trial by the investigator;",{"count":135,"type":21},90,[57],"To evaluate the effectiveness of light-blocking lenses in promoting emmetropization and reducing anisometropia in children with hyperopic anisometropia, and to assess the impact of light-intercepting lenses on visual function in this population.",[139,26],"Anisometropia",[139,26,116,117],{"date":121,"type":35},{"date":119,"type":21},{"date":124,"type":21},{"name":126,"class":42},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":15,"sex":16,"minAge":153,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":156,"conditions":157,"keywords":165,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":43},"100603365","my-eyes-my-light-amar-chokh-amar-alo-100603365","NCT07135570","\"My Eyes, My Light\": Amar Chokh, Amar Alo","Stop Blindness in Coastal Bangladesh: Testing the Effectiveness of Community-Based, Artificial Intelligence-Assisted Eye Disease Screening in Coastal Bangladesh","ACA2","Inclusion Criteria:\n\n* Age 35+ years\n* Residing in the Sub-District of Char Fasson in the Bhola District\n\nExclusion Criteria:\n\n* Known eye disease diagnosis","35 Years",{"count":155,"type":21},20000,"Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life. The primary conditions contributing to visual impairment and blindness include cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), refractive error, and presbyopia. Early detection of eye disease can provide substantial benefits in prompting treatment to reduce progression and mitigate disability.\n\nCompared with other regions, South Asia has the most cases of visual impairment due to cataracts and uncorrected refractive error. The combination of poverty, poor living and working environments, and limited health care access have long endangered eye health in Bangladesh. Coastal Bangladesh is particularly impacted by eye disease due to economic deprivation and limited healthcare access. The coastal population mostly works in fishing and agriculture, have prolonged sunlight exposure, and inadequate occupational eye protection. This low-lying region, with 35 million people, is especially vulnerable to climate disasters and global warming. High rates of chronic disease, especially diabetes mellitus Type 2 and hypertension, coupled with limited screening and treatment, shape the area's health profile, with the increasing prevalence of eye diseases such as DR, glaucoma, and visual impairment.\n\nTo address the issues of poor health, accessibility, and affordability of eye care, Artificial Intelligence (AI) applications, such as Artificial Intelligence (AI)-assisted fundus imaging, can be applied in eye screening. Medical AI applications have the potential to improve the quality and efficiency of healthcare, reduce healthcare costs, optimize treatment plans, and bolster the development of primary healthcare. They can identify presumptive DR, hypertensive retinopathy (HR), AMD, and glaucoma by analyzing the retina and optic disc of fundus images with moderate accuracy and high efficiency, thus helping address the lack of local eye care professionals.\n\nData Yakka developed a human-AI collaboration that delivers affordable and transformative community-based eye screening to underserved communities in the coastal Bangladesh region of Char Fasson. The \"Amar Chokh Amar Alo\" (My Eyes, My Light) initiative creates and implements comprehensive eye screening that combines AI-assisted eye screening and grassroots partnerships with trusted non-health non-governmental organizations (NGOs). It has three objectives: 1) Enhancing accessibility and affordability of eye screening; 2) Supporting high quality and efficient treatment of those problems detected via screening, 3) Collecting fundus images to refine or train AI algorithms in the future. This project was designed to evaluate the feasibility, performance, equity, and cost of this model of eye screening and its implications for global eye disease.\n\nThe implementation of participant recruitment, data collection, screening, and follow-up was separated into twelve steps. This standardized framework ensured the integration of screening with data collection and follow-up eye care services. Based on risk stratification by diabetes, hypertension, age 50+ years, and\u002For optometrist recommendation, fundus imaging was offered selectively to higher-risk patients.",[158,159,160,161,162,163,25,26,164],"Glaucoma","Diabetic Retinopathy (DR)","Hypertensive Retinopathy","Cataract","AMD - Age-Related Macular Degeneration","Presbyopia","Dacryocystitis",[166,167,168,169,170,171,172],"vision care","eye disease screening","cataracts","glaucoma","age-related macular degeneration","refractive error","Bangladesh","RECRUITING","2025-08-19",{"date":176,"type":35},"2025-08-22",{"date":178,"type":35},"2025-01-05",{"date":180,"type":21},"2026-06",{"name":182,"class":183},"Data Yakka, Inc.","INDUSTRY",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":15,"sex":16,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":55,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},"100561986","the-vis-opti-k-low-vision-aid-device-provides-vision-improvement-100561986","NCT06597292","The VIS Opti-K Low Vision Aid Device Provides Vision Improvement.","Vision Improvement for Patients With Presbyopia","Opti-K Pres","Inclusion Criteria\n\nSubjects who meet all of the following criteria are candidates for this study:\n\n1. Male or Female\n2. Any race\n3. Patient is at least 40 years old.\n4. Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s) to be treated.\n5. Patient has manifest refraction, spherical equivalent (MRSE) between -0.50 D to 2.50 D, with no more than 1.0 D of refractive cylinder, in eye(s) to be treated.\n6. Patient has uncorrected distance visual acuity (UDVA) of 20\u002F100 or better (i.e., LogMAR ≤ 0.70) in both eyes.\n7. Patient has best corrected distance visual acuity (CDVA) of 20\u002F20 or better (i.e., LogMAR ≤ 0.00) in both eyes.\n8. Patient has uncorrected near visual acuity (UNVA) between 20\u002F50 (LogMAR 0.40) and better than 20\u002F100 (LogMAR \\< 0.70) in eye(s) to be treated.\n9. Patient has best corrected near visual acuity (CNVA) of at least 20\u002F20 (LogMAR ≤ 0.00) in eye(s) to be treated.\n10. Patient requires reading adds of +1.0 to +3.0 D in eye(s) to be treated.\n11. Patient is not a contact lens (CL) wearer.\n12. Patient has normal corneal topography.\n13. Patient is willing and able to comply with all examinations.\n14. Patient must be competent to sign an informed consent form before study entry.\n\nExclusion Criteria\n\nSubjects who meet any of the following criteria are to be excluded from this study:\n\n1. Corneal disease or corneal disorder in either eye.\n2. Any active ocular surface disease of any severity.\n3. Increased IOP (above 20 mm Hg), glaucoma or history of glaucoma.\n4. Previous corneal surgery in the eye to be treated.\n5. Conjunctivochalasis\n6. Nystagnus\n7. Diabetes\n8. Pregnancy\n9. Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or that may confound the outcome of the study.\n\nnclusion Criteria: -\n\nExclusion Criteria:\n\n\\-","40 Years",{"count":85,"type":21},[57],"The VIS Opti-K Low Vision Aid device will be used to provide vision improvement to patients with refractive disorders (hyperopia and presbyopia).",[26,163],[198],"Vision improvement","2024-09-23",{"date":201,"type":35},"2024-09-25",{"date":203,"type":21},"2024-09-16",{"date":205,"type":21},"2026-12-30",{"name":207,"class":183},"VIS, Inc.",2]